watch cbsn live april 30 2020 11 45 am cbs news dr anthony fauci the nation s top infectious disease specialist is optimistic about the ability of the antiviral drug remdesivir produced by gilead sciences to shorten the time it takes seriously ill patients to recover from a covid 19 infection preliminary data analysis from an international covid 19 drug trial shows that remdesivir has a clear cut significant positive effect in diminishing the time to recovery fauci told reporters at the white house wednesday this development is really quite important for a number of reasons fauci said calling the data highly significant he said that the recovery time was reduced from 15 days to 11 days in the drug trial which involved over 1 000 hospitalized patients in the u s germany denmark spain greece and other countries and was he said the first truly high powered randomized placebo controlled trial for a coronavirus treatment although a 31 improvement doesn t seem like a knockout 100 it is a very important proof of concept fauci said adding that what it is proving is that a drug can block this virus the drug was administered as a daily iv for 10 days and was only tested in patients who were sick enough to be hospitalized the national institutes of healthsaid the trial began on february 21 fauci also said the mortality rate trended towards being better in the sense of less deaths in the remdesivir group at 8 for those treated with the drug versus 11 among those in the placebo group although he acknowledged that the difference seen in the study was not statistically significant fauci said the data still needs further analysis the reason fauci was announcing the outcome of the trial wednesday he said was that whenever there is clear evidence that a drug works you have an ethical obligation to let the people who were treated with the placebo know so that they can be treated with the drug however a separate study on a smaller group of patients in china published in the peer reviewed journal the lancet the same day found no benefit from the drug food and drug administration spokesman michael felberbaum said in a statement that the agency has been engaged in sustained and ongoing discussions with gilead sciences regarding making remdesivir available to patients as quickly as possible as appropriate the fda has not yet taken the step of issuing an emergency use authorization which allows unapproved medical products to be used in an emergency to treat serious diseases when there are no other adequate options sara cook and kristin brown contributed to this report first published on april 29 2020 6 03 pm 2020 cbs interactive inc all rights reserved be in the know get the latest breaking news delivered straight to your inbox copyright 2020 cbs interactive inc all rights reserved 